Compass Pathways CEO Shuts Down Questions On Rival Psilocybin Filing, Promises Own FDA Application In Two Weeks
Kabir Nath said Compass will finish its rolling application within two weeks and is preparing to launch in the first half of 2027.
Compass Pathways, which is developing COMP360, an investigational psilocybin treatment for treatment-resistant depression, will finish its rolling FDA application within two weeks, CEO Kabir Nath said on the company's third-quarter earnings call on Tuesday. Before taking questions, Nath said he was aware of "recent speculation regarding another potential filing" and would not comment on it.
Silence on the rival
Nath did not name the other company. "There's been no official statement and we will not be providing any comments on this matter," he said at the end of his prepared remarks, just before the question-and-answer session.
A Yahoo Finance report said Usona Institute had finished submitting its own psilocybin application and holds a similar priority voucher, and that Compass shares fell 28% on Monday.
An analyst from Stifel said he understood the company would not discuss the rival and asked, indirectly, how COMP360 would be pitched in a two-player market. Nath replied that the company's indication is treatment-resistant depression, then passed the question to Chief Commercial Officer Lori Englebert.
A one-to-two-month review clock
Nath said the national priority voucher sets a one-to-two-month review target for the FDA, leaving open the potential for a very rapid approval. Asked about scenarios, he said precedents vary but show a reasonably wide distribution around a median of about 60 days.
The application rests on two Phase 3 studies and a Phase 2b study that together enrolled more than a thousand patients, Nath said. The company is preparing to launch in the first half of 2027.
Englebert said the executive order on rescheduling concerns the Drug Enforcement Administration, and that states must also reschedule before the drug can be prescribed. She said states covering over 93% of the US population have said they intend to do so within 30 days of federal action.
Patents, payers and cash
Englebert said payers respond to proven efficacy in treatment-resistant patients. She said about 90% of interventional psychiatrists in recent market research would prescribe COMP360 within its first year, the highest willingness to prescribe she has seen in pre-launch research.
Nath said the polymorph patent family runs to 2038 before patent term restoration, and that earlier challenges to it, including appeals, were "completely rejected."
Chief Patient Officer Steve Levine contrasted a few COMP360 treatments, which he said could sustain effects for up to 12 months, with the 36 to 54 required per the Spravato label. Nath said $444 million in cash as of September 30 should carry Compass through the launch and into 2028.
Compass has about two weeks to complete the submission, after which the voucher's one-to-two-month review target begins to matter.
Sources
- COMPASS Pathways stock rebounds after earnings (CMPS:NASDAQ) | Seeking Alpha — seekingalpha.com
- Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027 — Yahoo Finance
- CMPS, HELP Stocks On Track For Worst Day In Months On Competitive FDA Psychedelic Race Fears — Yahoo Finance
- Compass points to unmet need as psychedelic nears market — fiercepharma.com
- Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights – Company Announcement - FT.com — Financial Times